GBIO (generationbio.com) Net Sales Margin

Brandmark of generationbio.com (GBIO)

Outsourcing development and production allows Generation Bio Co. (GBIO) to focus on science, which defines the current trend. The sales margin trajectory confirms this approach, while the -410.10 metric captures the current efficiency level. Stable demand for genomic medicine remains independent of GDP, and the implementation of robotic genome screening optimizes the creation of non-viral therapies, strengthening the business's financial resilience.

Generation Bio Co (GBIO) Net Margin: for the period 07/04/2022 - 02/21/2026

Analytical breakdowns and data insights for company Generation Bio (GBIO)

- share price and expert price forecast:
Comprehensive company analysis:Generation Bio, GBIO
Flagship merchandise of generationbio.com

Developing non-viral gene therapy requires colossal expenditures on laboratory infrastructure and biomaterial disposal for Generation Bio Co. (GBIO). This net profit margin measures the portion of final income in every dollar of revenue after deducting all expenses. This chart allows for an assessment of capital management efficiency amid high R&D costs. This price action reflects the business's ability to transform scientific research into actual profit. The stability of this indicator determines the level of market confidence in the issuer's financial sustainability.

Competitors of Generation Bio Co. (GBIO)

TEM: Net Sales Margin|Net Profitability Margin Qiagen QGEN|IONS (Isis Pharmaceuticals) - Net Sales Margin|Repligen Inc. - Net Profit Margin|Net Sales Margin RNA|CRSP - Net Margin|GeneDx - Return on Sales by Net Profit|Net Profit Rate RARE|Beam Tx - Net Sales Margin|SRPT - Net Sales Margin|TWST (Twist Bio) - Return on Sales by Net Profit|Net Return on Sales TXG|Return on Sales by Net Profit NTLA|Stoke Therapeutics Inc (STOK) - Company Sales Margin|Net Sales Margin BLFS|Net Margin WVE (Wave Life Sciences Corp)|Net Margin Maze Therapeutics MAZE|Net Profit Rate SION|PRME - Net Margin|Company Sales Margin Taysha TSHA|QURE: Net Sales Margin|Return on Sales by Net Profit MeiraGTx PLC|RGNX (REGENXBIO Inc) - Net Sales Margin|solidbio.com (SLDB) - Company Sales Margin|Net Margin Ocugen Corp (OCGN)|Pacific Biosciences of California, Inc. - Net Return on Sales|Benitec Biopharma - Return on Sales by Net Profit|DSGN: Net Return on Sales|RCKT: Return on Sales by Net Profit|FDMT - Net Sales Margin|LXEO: Net Sales Margin|Korro Bio Inc. - Net Profit Rate|EDIT (editasmedicine.com) - Net Sales Margin|Net Margin SLN|Net Margin ProQR Therapeutics NV (PRQR)|Codexis - Net Return on Sales|Net Margin Sangamo SGMO|NAUT: Net Return on Sales|MGX: Return on Sales by Net Profit|Net Margin Precision BioSciences|BOLD: Net Sales Margin|Net Return on Sales XCUR|Net Margin Imunon|Phio Pharmaceuticals - Net Profit Margin|Net Margin Mustang Bio, Inc. (MBIO)|Company Sales Margin TransCode Therapeutics, Inc.|Net Margin Bionano Genomics BNGO|Net Profit Rate APDN|BLUE - Net Margin|Net Profit Margin IPA|Omega Therapeutics, Inc. (OMGA) - Net Margin|Singular Genomics Corp (OMIC) - Net Sales Margin|RGLS (Regulus Therapeutics, Inc.) - Net Sales Margin|SYRS: Net Profit Rate|Return on Sales by Net Profit TBIO (Telesis Bio Inc.)|Net Sales Margin TRACON Pharmaceuticals Inc. (TCON)|Net Margin Unity Bio UBX